New ultrasound could replace painful liver biopsies
NCT ID NCT07128108
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study is testing a new ultrasound technique called visual transient elastography (ViTE) to measure liver fat and scarring in people with chronic liver injury. Researchers will compare the ultrasound results to the standard liver biopsy to see how accurate the new method is. About 225 adults aged 18-65 who recently had a liver biopsy will take part. The goal is to find clear cutoff values that can help diagnose liver problems without needing a needle biopsy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 225 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with liver injury
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Be aged 18-65 years. * Documented liver injury of any etiology with a liver biopsy performed within the past 2 weeks. * Willing to undergo Visual Transient Elastography (ViTE) examination using Mindray Hepatus 9 Ultrasound System and capable of providing written informed consent. Exclusion Criteria: * Acute viral hepatitis. * Right heart failure with either:Serum transaminases \>5× upper limit of normal (ULN),Total bilirubin \>85.5 μmol/L. * History of hepatocellular carcinoma (HCC). * Pregnancy. * Patients with implantable medical devices.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic liver injury are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
XinHua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200082, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Underactive thyroid may worsen liver scarring in fatty liver disease
- Sound waves may replace the needle in liver scarring tests
- Can a new ultrasound device spot liver damage without a biopsy?
- Can stem cells help infants with biliary atresia avoid a liver transplant?
- A protein supplement may fight fatty liver in teens
- Can extra doses of an old drug reverse liver scarring?